2020
The kinetics of humoral response and its relationship with the disease severity in COVID-19
Ren L, Zhang L, Chang D, Wang J, Hu Y, Chen H, Guo L, Wu C, Wang C, Wang Y, Wang Y, Wang G, Yang S, Dela Cruz CS, Sharma L, Wang L, Zhang D, Wang J. The kinetics of humoral response and its relationship with the disease severity in COVID-19. Communications Biology 2020, 3: 780. PMID: 33311543, PMCID: PMC7733479, DOI: 10.1038/s42003-020-01526-8.Peer-Reviewed Original ResearchConceptsHumoral responseDisease severityReceptor-binding domainAntibody titersSpike proteinSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2COVID-19Respiratory syndrome coronavirus 2Titers of NAbsGeometric mean titersCOVID-19 patientsSyndrome coronavirus 2Coronavirus disease 2019Disease courseMean titersCoronavirus 2Antibody responseIgG antibodiesRisk factorsIg levelsImmunoglobulin ADisease 2019Severe casesModerate infections
2018
2280. Antibiotic Exposure Does Not Impact Serological Responses to Rotavirus Vaccination
Anderson E, Lopman B, Yi J, Yildirim I, Creech C, El-Khorazaty J, Shane A, Edwards K. 2280. Antibiotic Exposure Does Not Impact Serological Responses to Rotavirus Vaccination. Open Forum Infectious Diseases 2018, 5: s675-s676. PMCID: PMC6255677, DOI: 10.1093/ofid/ofy210.1933.Peer-Reviewed Original ResearchGeometric mean titersAntibiotic exposureLogistic regression modelsRV vaccinesMultivariable logistic regression modelConcomitant antibiotic useRV immunizationLast doseVaccine doseVaccine groupImmunized childrenPrimary outcomeRotavirus immunizationAntibiotic administrationMean titersRegression modelsVaccine dosesSerological responseTreatment allocationAntibiotic useInclusion criteriaVaccine studiesImmune responseTreatment groupsSeroresponses
2015
Meningococcal Seroepidemiology 1 Year After the PsA-TT Mass Immunization Campaign in Burkina Faso
Tall H, Yaro S, Kpoda H, Ouangraoua S, Trotter C, Lafourcade B, Findlow H, Bai X, Martin C, Nwakamma I, Ouedraogo J, Gessner B, Borrow R, Mueller J. Meningococcal Seroepidemiology 1 Year After the PsA-TT Mass Immunization Campaign in Burkina Faso. Clinical Infectious Diseases 2015, 61: s540-s546. PMID: 26553686, PMCID: PMC4639492, DOI: 10.1093/cid/civ519.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAnimalsAntibodies, BacterialBlood Bactericidal ActivityBurkina FasoChildChild, PreschoolComplement System ProteinsFemaleHumansImmunoglobulin GInfantMaleMass VaccinationMeningitis, MeningococcalMeningococcal VaccinesNeisseria meningitidis, Serogroup ARabbitsSeroepidemiologic StudiesYoung AdultConceptsAntibody titersSerum bactericidal antibody titersVaccine-eligible age groupsBactericidal antibody titersGeometric mean titersAfrican meningitis beltPopulation-level immunitySpecific antibody titersMass immunization campaignOptimal vaccination strategyImmunoglobulin G concentrationLong-term controlPsA-TTMean titersVaccine coverageProtective antibodiesMeningitis beltBlood drawVaccination strategiesImmunization campaignRabbit complementGroup AHigh seroprevalenceStandardized interviewAge groups
2012
A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants
Agnandji S, Lell B, Fernandes J, Abossolo B, Methogo B, Kabwende A, Adegnika A, Mordmüller B, Issifou S, Kremsner P, Sacarlal J, Aide P, Lanaspa M, Aponte J, Machevo S, Acacio S, Bulo H, Sigauque B, Macete E, Alonso P, Abdulla S, Salim N, Minja R, Mpina M, Ahmed S, Ali A, Mtoro A, Hamad A, Mutani P, Tanner M, Tinto H, D'Alessandro U, Sorgho H, Valea I, Bihoun B, Guiraud I, Kaboré B, Sombié O, Guiguemdé R, Ouédraogo J, Hamel M, Kariuki S, Oneko M, Odero C, Otieno K, Awino N, McMorrow M, Muturi-Kioi V, Laserson K, Slutsker L, Otieno W, Otieno L, Otsyula N, Gondi S, Otieno A, Owira V, Oguk E, Odongo G, Woods J, Ogutu B, Njuguna P, Chilengi R, Akoo P, Kerubo C, Maingi C, Lang T, Olotu A, Bejon P, Marsh K, Mwambingu G, Owusu-Agyei S, Asante K, Osei-Kwakye K, Boahen O, Dosoo D, Asante I, Adjei G, Kwara E, Chandramohan D, Greenwood B, Lusingu J, Gesase S, Malabeja A, Abdul O, Mahende C, Liheluka E, Malle L, Lemnge M, Theander T, Drakeley C, Ansong D, Agbenyega T, Adjei S, Boateng H, Rettig T, Bawa J, Sylverken J, Sambian D, Sarfo A, Agyekum A, Martinson F, Hoffman I, Mvalo T, Kamthunzi P, Nkomo R, Tembo T, Tegha G, Tsidya M, Kilembe J, Chawinga C, Ballou W, Cohen J, Guerra Y, Jongert E, Lapierre D, Leach A, Lievens M, Ofori-Anyinam O, Olivier A, Vekemans J, Carter T, Kaslow D, Leboulleux D, Loucq C, Radford A, Savarese B, Schellenberg D, Sillman M, Vansadia P. A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants. New England Journal Of Medicine 2012, 367: 2284-2295. PMID: 23136909, PMCID: PMC10915853, DOI: 10.1056/nejmoa1208394.Peer-Reviewed Original ResearchConceptsPhase 3 trialVaccine efficacySevere malariaWeeks of ageProtocol populationTreat populationClinical malariaCandidate malaria vaccine RTSOngoing phase 3 trialsAnti-circumsporozoite antibodiesMalaria vaccine RTSCoprimary end pointsSerious adverse eventsGeometric mean titersMonths of ageComparator vaccineAdverse eventsFirst doseFirst vaccinationMalaria episodesThird doseMean titersCox regressionMalaria vaccineAfrican infants
2001
Lymphotoxin-alpha deficiency completely protects C57BL/6 mice from developing clinical experimental autoimmune myasthenia gravis
Goluszko E, Hjelmström P, Deng C, Poussin M, Ruddle N, Christadoss P. Lymphotoxin-alpha deficiency completely protects C57BL/6 mice from developing clinical experimental autoimmune myasthenia gravis. Journal Of Neuroimmunology 2001, 113: 109-118. PMID: 11137582, DOI: 10.1016/s0165-5728(00)00420-3.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntigens, CDAutoantibodiesB7-2 AntigenGene ExpressionImmunodominant EpitopesImmunoglobulin GImmunoglobulin MLymphotoxin-alphaMembrane GlycoproteinsMiceMice, Inbred C57BLMice, KnockoutMyasthenia Gravis, Autoimmune, ExperimentalReceptors, CholinergicReceptors, Tumor Necrosis FactorSpleenConceptsExperimental autoimmune myasthenia gravisClinical experimental autoimmune myasthenia gravisAutoimmune myasthenia gravisMyasthenia gravisMean titersPrimary humoral immune responseAlpha-deficient miceAnti-AChR antibodiesHumoral immune responseLower mean titersC57BL/6 miceImmunized miceTotal IgGDeficient miceIgG isotypeImmune responseAcetylcholine receptorsPartial preventionGravisMiceComplete preventionTitersLtPreventionPathogenesis
1998
Serologic and Molecular Evidence of Human Herpesvirus 8 Activation in Renal Transplant Recipients
Hudnall S, Rady P, Tyring S, Fish J. Serologic and Molecular Evidence of Human Herpesvirus 8 Activation in Renal Transplant Recipients. The Journal Of Infectious Diseases 1998, 178: 1791-1794. PMID: 9815236, DOI: 10.1086/314482.Peer-Reviewed Original ResearchConceptsRenal transplant patientsGeometric mean titersHealthy adultsTransplant patientsPolymerase chain reactionRenal transplant populationRenal transplant recipientsHIV-positive adultsHuman immunodeficiency virusViral DNATransplant recipientsTransplant groupTransplant populationMean titersImmunodeficiency virusImmunocompromised populationsSerum antibodiesKaposi's sarcomaPositive adultsSerologic resultsIndirect immunofluorescenceWhole bloodChain reactionAdultsPatients
1990
Influenza outbreaks in nursing homes: how effective is influenza vaccine in the institutionalized elderly?
Cartter M, Renzullo P, Helgerson S, Martin S, Jekel J. Influenza outbreaks in nursing homes: how effective is influenza vaccine in the institutionalized elderly? Infection Control And Hospital Epidemiology 1990, 11: 473-8. PMID: 2230050, DOI: 10.1086/646214.Peer-Reviewed Original ResearchConceptsNursing homesUnvaccinated residentsClinical illnessVaccine effectivenessThird outbreakInfluenza outbreaksInfluenza vaccination ratesInfluenza vaccine effectivenessGeometric mean titersHemagglutination inhibition antibodiesVaccinated residentsConnecticut nursing homesInfluenza seasonInfluenza vaccineMean titersVaccination ratesHI antibodyInfluenza ARelative riskHI titersRetrospective investigationIllnessTitersAntibodiesOutbreak
1987
EPIZOOTIOLOGY OF HANTAVIRUS INFECTIONS IN BALTIMORE: ISOLATION OF A VIRUS FROM NORWAY RATS, AND CHARACTERISTICS OF INFECTED RAT POPULATIONS
CHILDS J, KORCH G, GLASS G, LEDUC J, SHAH K. EPIZOOTIOLOGY OF HANTAVIRUS INFECTIONS IN BALTIMORE: ISOLATION OF A VIRUS FROM NORWAY RATS, AND CHARACTERISTICS OF INFECTED RAT POPULATIONS. American Journal Of Epidemiology 1987, 126: 55-68. PMID: 3109236, DOI: 10.1093/oxfordjournals.aje.a114662.Peer-Reviewed Original ResearchConceptsHantavirus infectionGeometric mean titersPrevalence of antibodiesAntibody prevalence ratesAntibody reactivity patternsMonoclonal antibody reactivity patternsAge-related mechanismsMean titersSerologic testsHigh prevalenceInfected ratsPrevalence ratesPresence of ratsRatsInfectionEnzootic natureUrban ratsSix-year periodHuman exposureRat massVirusPrevalenceAntibodiesHantavirusesUnited States
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply